Helus, Pharma

Helus Pharma Shares Slide 16% as Strong Phase-3 Data Collide With a Ballooning Loss

Published on 11/16/2026 at 16:50 | Editorial boerse-global.de
Helus Pharma shares dropped 16% after Phase-3 HLP003 results showed a 7.6-point MADRS gain at six weeks, alongside a wider half-year loss and safety events.
Helus Pharma Inc. Illustration mit AI erstellt.

Helus Pharma's Friday disclosure of headline Phase-3 results for its depression candidate HLP003 landed alongside fresh interim financials, and investors voted with their feet. The stock fell 16% to 7,47 USD, giving back ground from the prior session's close of 8,87 USD.

Efficacy Holds Up at Both Time Points

The APPROACH trial, which tests HLP003 as an add-on therapy for major depressive disorder, delivered a placebo-adjusted change of minus 7,6 points on the MADRS scale at six weeks. By week twelve, the gap versus placebo stood at minus 7,0 points. Helus Pharma reported a p-value below 0,0001 at each of the two time points.

Bundled into the company's characterization of the data as positive were three serious adverse events tied to treatment — a safety signal disclosed in the same release as the efficacy figures.

Should investors sell immediately? Or is it worth buying Helus Pharma Inc.?

Half-Year Loss Swells on Equity Compensation

The interim statements for the second quarter of fiscal 2027, filed the same day, cover both the three-month period and the six months to 30 September. For the half-year, the net loss reached US$150,91 million, a figure that includes US$76,5 million in share-based compensation expenses. Helus Pharma attributed that line item largely to events connected with remuneration through equity instruments.

Stripping out the half-year total, the stand-alone second quarter produced a net loss of 103,1 million US$, far above the 33,7 million US$ recorded in the same quarter a year earlier.

Cash Position and Burn Rate

Operating activities consumed 35,3 million US$ in cash during the reporting quarter. As of 30 September, the company held 171,1 million US$ in cash. The filings also included the accompanying management discussion and analysis.

Webcast Puts Data in Front of Investors

Helus Pharma had flagged a day earlier that it would present the first summary of APPROACH results via webcast, and that presentation anchored Friday's agenda. The equity reaction suggests the market weighed the expanded loss and the safety disclosures more heavily than the statistical strength of the MADRS separation.

Ad

Helus Pharma Inc. Stock: New Analysis - 16 November

Fresh Helus Pharma Inc. information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Helus Pharma Inc. analysis...

Disclaimer...
en | CA23256X4075 | HELUS | boerse | 70521664 |